Accelrys Transforms Innovation by Bridging Cheminformatics and Bioinformatics
SAN DIEGO, Sept.10, 2013 /PRNewswire/ — Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management software, has announced the completion of an initiative to standardize chemical structure perception across the Accelrys Enterprise Platform and the Accelrys Direct data cartridge for Oracle. Harmonized cheminformatics technology from Accelrys enables scientists to represent molecules, reactions, biologics and conjugates consistently across applications developed using the Accelrys Enterprise Platform and Accelrys Direct.
New releases of Accelrys Chemical Registration and Accelrys Biological Registration leverage the capabilities of Accelrys Direct to provide consistent registration of small molecules, biologics, chemically modified biologics and conjugates. The Accelrys registration applications enable organizations to capture and secure intellectual property (IP) pertaining to molecules and biologics in an environment that improves efficiency, protects IP, lowers costs associated with the unnecessary production of duplicate entities and improves traceability for regulatory agencies.
“With pharma and biotech companies moving to portfolios spanning small molecules, biologics and antibodies, medicinal chemists and molecular biologists must register and track an extensive set of entities,” said Matt Hahn, Ph.D., senior vice president and chief technology officer, Accelrys. “The Accelrys Cheminformatics Suite, anchored by Accelrys Direct and our chemical and biological registration applications, meets customers’ fundamental needs for end-to-end combined chemical and biologics acquisition, registration and management in today’s increasingly integrated chemical and biological R&D environment.”
The Accelrys Direct data cartridge ensures the fidelity of chemical information across Accelrys solutions and enables multidisciplinary project teams to explore novel chemical structures and macromolecular sequences stored in a single corporate registry. Accelrys Direct offers proven performance with databases containing more than 69 million structures and more than 17 million reactions. Accelrys Direct 9.0 provides harmonized chemistry representation, perception and search with Accelrys Enterprise Platform 9.0 along with other new features and enhancements. The Accelrys Enterprise Platform is the foundation for Accelrys’ scientific software and services, enabling organizations to access and gain value from complex data across the enterprise and to integrate and deploy broad scientific solutions from research and development through quality control and manufacturing.
Built on the Accelrys Enterprise Platform, Accelrys Chemical Registration is a flexible, fully featured, out-of-the-box solution for building, managing and searching corporate substance and batch data bases, enabling researchers to register single substances, load SDfiles and leverage comprehensive functionality to meet multiple registration needs. Accelrys Chemical Registration 3.2 provides an interface to theAccelrys Electronic Lab Notebook that enables direct registration from an experiment. The latest release also supports data mirroring to Accelrys ISIS- and Isentris-based registration systems in addition to existing support for mirroring to Accelrys Accord-based enterprise informatics registration systems.
Accelrys Biological Registration enables biologists to register, search and report on a variety of biological entities including antibodies, hybridomas, cell lines, plasmids, proteins, siRNAs, yeasts, vaccines and more. Built in close collaboration with top pharmaceutical companies, this award-winning system helps manage intellectual assets, improve operational efficiency and can be readily extended to meet specific customer needs without writing code. Accelrys Biological Registration 3.1 provides new capabilities for defining chemically modified biological entities such as PEGylated peptides and antibody drug conjugates through support of chemical structure attributes, chemistry attribute rules and chemistry searching.
To learn more about the Accelrys Cheminformatics Suite and our next-generation collaborative discovery research solution, join us at the 11th Annual Pharmaceutical IT Congress, Sept. 23-24, in London. Rob Brown, Ph.D., senior director life sciences product management and marketing, will present on Accelrys’ “Next Generation Cheminformatics Suite for Enhancing R&D Productivity and Innovation” on Monday, Sept. 23 at 12.20 p.m.
To learn more about Accelrys Biological Registration and its capabilities to register chemically modified biologics, sign up for a complimentary webinar to be held on Tuesday, Dec. 10 at 8 a.m. PST entitled “Accelrys Transforms Innovation by Bridging Cheminformatics and Bioinformatics.”
About Accelrys, Inc.
Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management solutions, supports industries and organizations that rely on scientific innovation to differentiate themselves. The industry-leading Accelrys Enterprise Platform provides a broad and flexible scientific solution optimized to integrate the diversity of science, experimental processes and information requirements across the research, development, process scale-up and manufacturing phases of product development. By incorporating capabilities in applications for modeling and simulation, enterprise lab management, workflow and automation, and data management and informatics, Accelrys enables scientific innovators to access, organize, analyze and share data in unprecedented ways, ultimately enhancing innovation, improving productivity and compliance, reducing costs and speeding time from lab to market.
Accelrys solutions are used by more than 1,300 companies in the pharmaceutical, biotechnology, energy, chemicals, aerospace, consumer packaged goods and industrial products industries. Headquartered inSan Diego, California, USA, Accelrys employs more than 200 full-time PhD scientists. For more information about Accelrys, visit www.accelrys.com.
